Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 3Endocrine 3Genitourinary 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 135Small Cell Lung Carcinoma 51Lung Neoplasms 45Melanoma 15Carcinoma, Renal Cell 14Carcinoma, Transitional Cell 10Stomach Neoplasms 9Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Hepatocellular 9Mesothelioma, Malignant 8Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Breast Neoplasms 6Uterine Cervical Neoplasms 5Neoplasm Metastasis 5Kidney Neoplasms 5Carcinoma, Merkel Cell 5Thoracic Neoplasms 4Carcinoma, Neuroendocrine 4Small Cell Lung Cancer Extensive Stage 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Mesothelioma 3Lung Diseases 3Gastrointestinal Neoplasms 3Esophageal Neoplasms 3Brain Neoplasms 3

Interventions

Nivolumab 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2fludarabine 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Irinotecan 2Fluorodeoxyglucose F18 2Everolimus 2Carboplatin 2tislelizumab 1taxane 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1olaparib 1liposomal doxorubicin 1entrectinib 1cabozantinib 1atezolizumab 1alectinib 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1RRx-001 1Quality of Life 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × atezolizumab × Thoracic × Clear all
NCT04471727 2026-02-24

MK-6070-001

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1/2 Active not recruiting
232 enrolled
EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡